Cargando…
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494850/ https://www.ncbi.nlm.nih.gov/pubmed/32938904 http://dx.doi.org/10.1038/s41408-020-00358-3 |
| _version_ | 1783582812361719808 |
|---|---|
| author | Gentile, Massimo Martino, Enrica Antonia Visentin, Andrea Coscia, Marta Reda, Gianluigi Sportoletti, Paolo Mauro, Francesca Romana Laurenti, Luca Varettoni, Marzia Murru, Roberta Chiarenza, Annalisa Vigna, Ernesto Mendicino, Francesco Lucia, Eugenio Bossio, Sabrina Recchia, Anna Grazia Moia, Riccardo Pietrasanta, Daniela Loseto, Giacomo Consoli, Ugo Scortechini, Ilaria Rossi, Francesca Maria Zucchetto, Antonella Al-Janazreh, Hamdi Vitale, Candida Tripepi, Giovanni D’Arrigo, Graziella Angeletti, Ilaria Bomben, Riccardo Neri, Antonino Cutrona, Giovanna Fronza, Gilberto Di Raimondo, Francesco Gaidano, Gianluca Cuneo, Antonio Foà, Robin Ferrarini, Manlio Trentin, Livio Gattei, Valter Morabito, Fortunato |
| author_facet | Gentile, Massimo Martino, Enrica Antonia Visentin, Andrea Coscia, Marta Reda, Gianluigi Sportoletti, Paolo Mauro, Francesca Romana Laurenti, Luca Varettoni, Marzia Murru, Roberta Chiarenza, Annalisa Vigna, Ernesto Mendicino, Francesco Lucia, Eugenio Bossio, Sabrina Recchia, Anna Grazia Moia, Riccardo Pietrasanta, Daniela Loseto, Giacomo Consoli, Ugo Scortechini, Ilaria Rossi, Francesca Maria Zucchetto, Antonella Al-Janazreh, Hamdi Vitale, Candida Tripepi, Giovanni D’Arrigo, Graziella Angeletti, Ilaria Bomben, Riccardo Neri, Antonino Cutrona, Giovanna Fronza, Gilberto Di Raimondo, Francesco Gaidano, Gianluca Cuneo, Antonio Foà, Robin Ferrarini, Manlio Trentin, Livio Gattei, Valter Morabito, Fortunato |
| author_sort | Gentile, Massimo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7494850 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74948502020-10-01 Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab Gentile, Massimo Martino, Enrica Antonia Visentin, Andrea Coscia, Marta Reda, Gianluigi Sportoletti, Paolo Mauro, Francesca Romana Laurenti, Luca Varettoni, Marzia Murru, Roberta Chiarenza, Annalisa Vigna, Ernesto Mendicino, Francesco Lucia, Eugenio Bossio, Sabrina Recchia, Anna Grazia Moia, Riccardo Pietrasanta, Daniela Loseto, Giacomo Consoli, Ugo Scortechini, Ilaria Rossi, Francesca Maria Zucchetto, Antonella Al-Janazreh, Hamdi Vitale, Candida Tripepi, Giovanni D’Arrigo, Graziella Angeletti, Ilaria Bomben, Riccardo Neri, Antonino Cutrona, Giovanna Fronza, Gilberto Di Raimondo, Francesco Gaidano, Gianluca Cuneo, Antonio Foà, Robin Ferrarini, Manlio Trentin, Livio Gattei, Valter Morabito, Fortunato Blood Cancer J Correspondence Nature Publishing Group UK 2020-09-16 /pmc/articles/PMC7494850/ /pubmed/32938904 http://dx.doi.org/10.1038/s41408-020-00358-3 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Correspondence Gentile, Massimo Martino, Enrica Antonia Visentin, Andrea Coscia, Marta Reda, Gianluigi Sportoletti, Paolo Mauro, Francesca Romana Laurenti, Luca Varettoni, Marzia Murru, Roberta Chiarenza, Annalisa Vigna, Ernesto Mendicino, Francesco Lucia, Eugenio Bossio, Sabrina Recchia, Anna Grazia Moia, Riccardo Pietrasanta, Daniela Loseto, Giacomo Consoli, Ugo Scortechini, Ilaria Rossi, Francesca Maria Zucchetto, Antonella Al-Janazreh, Hamdi Vitale, Candida Tripepi, Giovanni D’Arrigo, Graziella Angeletti, Ilaria Bomben, Riccardo Neri, Antonino Cutrona, Giovanna Fronza, Gilberto Di Raimondo, Francesco Gaidano, Gianluca Cuneo, Antonio Foà, Robin Ferrarini, Manlio Trentin, Livio Gattei, Valter Morabito, Fortunato Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab |
| title | Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab |
| title_full | Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab |
| title_fullStr | Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab |
| title_full_unstemmed | Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab |
| title_short | Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab |
| title_sort | validation of a survival-risk score (srs) in relapsed/refractory cll patients treated with idelalisib–rituximab |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494850/ https://www.ncbi.nlm.nih.gov/pubmed/32938904 http://dx.doi.org/10.1038/s41408-020-00358-3 |
| work_keys_str_mv | AT gentilemassimo validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT martinoenricaantonia validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT visentinandrea validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT cosciamarta validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT redagianluigi validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT sportolettipaolo validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT maurofrancescaromana validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT laurentiluca validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT varettonimarzia validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT murruroberta validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT chiarenzaannalisa validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT vignaernesto validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT mendicinofrancesco validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT luciaeugenio validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT bossiosabrina validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT recchiaannagrazia validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT moiariccardo validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT pietrasantadaniela validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT losetogiacomo validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT consoliugo validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT scortechiniilaria validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT rossifrancescamaria validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT zucchettoantonella validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT aljanazrehhamdi validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT vitalecandida validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT tripepigiovanni validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT darrigograziella validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT angelettiilaria validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT bombenriccardo validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT neriantonino validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT cutronagiovanna validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT fronzagilberto validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT diraimondofrancesco validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT gaidanogianluca validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT cuneoantonio validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT foarobin validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT ferrarinimanlio validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT trentinlivio validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT gatteivalter validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab AT morabitofortunato validationofasurvivalriskscoresrsinrelapsedrefractorycllpatientstreatedwithidelalisibrituximab |